StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a report issued on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
BioLineRx Stock Up 1.7 %
Shares of BioLineRx stock opened at $0.47 on Tuesday. BioLineRx has a 52-week low of $0.43 and a 52-week high of $1.93. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The business’s 50 day simple moving average is $0.61 and its 200 day simple moving average is $0.66. The firm has a market cap of $37.56 million, a PE ratio of -0.62 and a beta of 1.46.
BioLineRx (NASDAQ:BLRX – Get Free Report) last announced its earnings results on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. The business had revenue of $5.39 million for the quarter, compared to analyst estimates of $3.93 million. On average, analysts predict that BioLineRx will post -0.25 earnings per share for the current fiscal year.
Institutional Investors Weigh In On BioLineRx
BioLineRx Company Profile
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Recommended Stories
- Five stocks we like better than BioLineRx
- The Most Important Warren Buffett Stock for Investors: His Own
- Survey Reveals: America’s Most Coveted Businesses in 2024
- 10 Best Airline Stocks to Buy
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Best Aerospace Stocks Investing
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.